28-day mortality: IL-6 positive: 43.6% (afelimomab) vs. 47.6% (placebo), 5.8% risk reduction (p = 0.041). IL-6 negative: 25.5% vs. 28.6%. All patients: 32.2% vs. 35.9%.Organ dysfunction: Faster improvement and greater TNF/IL-6 reduction with afelimomab. Safety: Similar AE rates, HAMA formation 23.6% vs. 6.3% placebo (no clinical impact), no increase in secondary infections. This evidence concerns the gene TNF and infection.